Advanced

Prediction of outcome after diagnosis of metachronous contralateral breast cancer.

Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Fernö, Mårten LU ; Manjer, Jonas LU and Rydén, Lisa LU (2011) In BMC Cancer 11.
Abstract
BACKGROUND: Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis.



METHODS:

Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.



RESULTS:

The cohort included 723 patients with metachronous... (More)
BACKGROUND: Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis.



METHODS:

Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.



RESULTS:

The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS.



CONCLUSIONS:

In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Cancer
volume
11
publisher
BioMed Central
external identifiers
  • WOS:000289717500001
  • PMID:21450091
  • Scopus:79954602547
ISSN
1471-2407
DOI
10.1186/1471-2407-11-114
language
English
LU publication?
yes
id
73dec3c5-2884-45db-a9c2-5f0f716fb194 (old id 1937735)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21450091?dopt=Abstract
date added to LUP
2011-05-02 08:56:13
date last changed
2016-10-13 04:26:52
@misc{73dec3c5-2884-45db-a9c2-5f0f716fb194,
  abstract     = {BACKGROUND: Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis.<br/><br>
<br/><br>
METHODS:<br/><br>
Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.<br/><br>
<br/><br>
RESULTS:<br/><br>
The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged &lt;50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p &lt; 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS.<br/><br>
<br/><br>
CONCLUSIONS:<br/><br>
In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.},
  author       = {Alkner, Sara and Bendahl, Pär-Ola and Fernö, Mårten and Manjer, Jonas and Rydén, Lisa},
  issn         = {1471-2407},
  language     = {eng},
  publisher    = {ARRAY(0xb4b62d0)},
  series       = {BMC Cancer},
  title        = {Prediction of outcome after diagnosis of metachronous contralateral breast cancer.},
  url          = {http://dx.doi.org/10.1186/1471-2407-11-114},
  volume       = {11},
  year         = {2011},
}